Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • Challenge: Inducing tumour-specific immunity and preventing escape

Based on our research into mechanisms of antigen processing in tumours, Oxford researchers are identifying candidate tumour vaccine epitopes that are optimal for T cell activation, resistant to escape from cancer mutations, and epigenetic changes targeting the antigen processing pathway and less prone to induce T cell exhaustion. In work linked to the Cancer Big Data theme, and leveraging Oxford spinout SingulaBio, we will develop better algorithms to predict antigenicity and immunogenicity of tumour antigens to inform adoptive T cell therapy in ovarian cancer, CAR-TcR therapy in AML and for vaccine design in multiple cancers.